When COVID-19 restrictions went into place in early 2020, the life sciences industry was forced to stress test their ability to work and conduct clinical research remotely.

Solutions, applications, and ideas touted as “next generation” were quickly implemented alongside established concepts and technologies including:

• PRO via mobile/BYOD devices
• Sensors and wearables for new digital endpoints
• Direct-to-patient medication delivery
• Home-based consent and reconsent

This article explains how pandemic restrictions compelled the industry to change practically overnight, and how these changes improve clinical operations.